Showing 411-420 of 20873 results for "".
- Innovative Approaches to Managing Diabetic Peripheral Neuropathyhttps://reachmd.com/news/innovative-approaches-to-managing-diabetic-peripheral-neuropathy-dpn/2474554/Diabetic peripheral neuropathy (DPN) remains a prevalent and debilitating complication of diabetes, often leading to significant morbidity. Recent innovations in therapeutic strategies are offering new avenues for clinicians to enhance patient outcomes and quality of life.<
- New Target for Treating Diabetic Cardiomyopathy Identifiedhttps://reachmd.com/news/new-target-for-treating-diabetic-cardiomyopathy-identified/2468762/Advances in understanding diabetic cardiomyopathy have revealed a potential therapeutic target for a disease that currently has no specific treatments. Diabetic cardiomyopathy, a progressive heart condition that is independent of hypertension or other cardiovascular disorders, is one of th
- High Oxygen Levels Show Limited Impact on Chemoreceptor Overactivity in Type 2 Diabeteshttps://reachmd.com/news/high-oxygen-levels-show-limited-impact-on-chemoreceptor-overactivity-in-type-2-diabetes/2470799/Could manipulating oxygen levels help manage cardiovascular and metabolic disorders? Researchers from the University of Missouri sought to answer this question by exploring the role of peripheral chemoreceptors—specialized cells near the carotid artery—in conditions like high blo
- FDA Clears First Automated Device to Deliver Insulin to People with Type 2 Diabeteshttps://reachmd.com/news/fda-clears-first-automated-device-to-deliver-insulin-to-people-with-type-2-diabetes/2467971/by Robin Foster
- Largest Study of Its Kind Finds New Genetic Risk Factors for Type 2 Diabeteshttps://reachmd.com/news/largest-study-of-its-kind-finds-new-genetic-risk-factors-for-type-2-diabetes/2462322/
- Topical Ruxolitinib Gel in Prurigo Nodularis: Phase I/II Trialhttps://reachmd.com/news/topical-ruxolitinib-gel-in-prurigo-nodularis-phase-iii-trial/2487677/Key Takeaways This phase I/II, randomized, double-blind, vehicle-controlled, multicenter trial in China assigned 49 adults with prurigo nodularis 2:1 to HDM3010 or vehicle across once-daily and twice-daily cohorts. Treatment-emergent events were infreq
- EMA Validates Bristol Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy for First-Line Treatment of Unresectable or Advanced HCChttps://reachmd.com/news/ema-validates-bristol-myers-squibbs-type-ii-variation-application-for-opdivo-plus-yervoy-for-first-line-treatment-of-unresectable-or-advanced-hcc/2467580/Bristol Myers Squibb announced that the European Medicines Agency (EMA) validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) a
- Innovative Approaches to Reversing Age-Related Vision Losshttps://reachmd.com/news/innovative-approaches-to-reversing-age-related-vision-loss/2483545/The promise of lipid restoration strategies to address age-related visual decline has garnered attention, with early-stage research suggesting retinal lipid modulation may improv
- Gene Therapy and Systemic Interventions in Diabetic Eye Diseasehttps://reachmd.com/news/gene-therapy-and-systemic-interventions-in-diabetic-eye-disease/2474557/Diabetic retinopathy and macular edema remain leading causes of vision impairment among individuals with diabetes, presenting significant challenges in ophthalmic care. Emerging gene therapy techniques are being explored to deliver anti-angiogenic proteins that inhibit vascular endothel
- Evaluating the Efficacy of Medical Apps for Diabetes and Heart Disease: Insights from Recent Researchhttps://reachmd.com/news/evaluating-the-efficacy-of-medical-apps-for-diabetes-and-heart-disease-insights-from-recent-research/2471234/Recent research led by the Technical University of Munich questions the true efficacy of telemedicine and exercise apps for managing type 2 diabetes and coronary heart disease, calling for a reevaluation of treatment priorities in patient care.